-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Less than a week after the opening of 2022, the Science and Technology Innovation Board welcomed a new pharmaceutical stock - Asieris Pharmaceuticals.
Since this is a pharmaceutical company with "no revenue and no products", it was listed for the first time.
Whether Japan will "break" has also attracted the attention of the industry
.
According to the data, Asieris was established in 2010 and is a subdivided company in the field of oncology drug research and development, focusing on a global innovative drug company in the fields of urogenital tumors and other major diseases
.
The company has been losing money for four consecutive years.
From 2018 to 2020, the new pharmaceutical shares lost 59.
936 million yuan, 172 million yuan and 247 million yuan respectively; in the first three quarters of 2021, the company achieved a net loss of 172 million yuan
.
Up to now, the company's core products are in the research and development state and have not yet been listed
.
From the perspective of product pipeline, the prospectus shows that the company has 9 products and 12 research projects, but among all products, only 3 studies corresponding to APL-1202 and APL-1702 are already in pivotal or Phase III clinical trials Most of the other projects are still in the early stages of research and development
.
APL-1202 is a product for the treatment of non-muscle invasive bladder cancer (hereinafter referred to as NMIBC), and is the world's first oral, reversible methionine aminopeptidase type II ( MetAP2) inhibitor
.
The global bladder cancer market is huge, reaching US$3.
8 billion in 2020, and is expected to reach US$9 billion in 2025 and US$15.
1 billion in 2030
.
Another data show that in 2020, of the 573,000 new bladder cancer patients worldwide, about 75% are NMIBC patients
.
In China, surgical resection is the standard treatment for NMIBC patients, supplemented by bladder chemical perfusion therapy and immune perfusion therapy to prevent recurrence and progression, but there are still large unmet needs.
.
It is expected in the industry that if Asieris' APL-1202 is successfully launched, it may become the first approved treatment for NMIBC with chemotherapy perfusion recurrence
.
APL-1702 is mainly used for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by infection of all HPV virus subtypes.
The product has been approved for international multi-center phase III clinical trials and is expected to Providing a new non-surgical treatment option can reduce the pain and side effects of surgical treatment for patients, especially to avoid the impact of surgery on the reproductive function of patients of reproductive age
.
In 2020, the number of HSIL patients in China is about 2 million, and the number is still growing
.
According to Asieris Pharma's forecast, the peak market penetration rates of APL-1202 and APL-1702 are 10%-50% and 10%-25% respectively, corresponding to a market space of RMB 1.
639 billion to RMB 4.
685 billion and RMB 1.
959 billion to RMB 4.
897 billion, respectively.
billion
.
It is worth mentioning that the two products, APL-1202 and APL-1702, were purchased by Asieris, not independently developed, and some of the core technologies of the two core products will cost more than 1 billion yuan.
It's a lot of pressure for a company with revenue
.
At the same time, the industry also pointed out that Asieris' core products also have competitors.
For example, in the domestic NMIBC field, in addition to Asieris' APL-1202, there are 6 innovative drugs of other companies in clinical stage; In the field of HSIL treatment, there are also 3 domestic therapeutic drugs targeting HSIL or CIN2/3 that have entered clinical trials
.
In addition, because the company has no sales team experience
.
In this regard, Asieris pointed out in the prospectus that in the future, the company's sales team may not be able to grasp the market demand for new drugs in a timely manner, respond to and serve the market in a timely manner, and the recruitment progress of the sales team is not as good as expected, and the loss of the sales team in the short term after entry.
These risks will have certain adverse effects on the commercialization of drugs
.
Since this is a pharmaceutical company with "no revenue and no products", it was listed for the first time.
Whether Japan will "break" has also attracted the attention of the industry
.
According to the data, Asieris was established in 2010 and is a subdivided company in the field of oncology drug research and development, focusing on a global innovative drug company in the fields of urogenital tumors and other major diseases
.
The company has been losing money for four consecutive years.
From 2018 to 2020, the new pharmaceutical shares lost 59.
936 million yuan, 172 million yuan and 247 million yuan respectively; in the first three quarters of 2021, the company achieved a net loss of 172 million yuan
.
Up to now, the company's core products are in the research and development state and have not yet been listed
.
From the perspective of product pipeline, the prospectus shows that the company has 9 products and 12 research projects, but among all products, only 3 studies corresponding to APL-1202 and APL-1702 are already in pivotal or Phase III clinical trials Most of the other projects are still in the early stages of research and development
.
APL-1202 is a product for the treatment of non-muscle invasive bladder cancer (hereinafter referred to as NMIBC), and is the world's first oral, reversible methionine aminopeptidase type II ( MetAP2) inhibitor
.
The global bladder cancer market is huge, reaching US$3.
8 billion in 2020, and is expected to reach US$9 billion in 2025 and US$15.
1 billion in 2030
.
Another data show that in 2020, of the 573,000 new bladder cancer patients worldwide, about 75% are NMIBC patients
.
In China, surgical resection is the standard treatment for NMIBC patients, supplemented by bladder chemical perfusion therapy and immune perfusion therapy to prevent recurrence and progression, but there are still large unmet needs.
.
It is expected in the industry that if Asieris' APL-1202 is successfully launched, it may become the first approved treatment for NMIBC with chemotherapy perfusion recurrence
.
APL-1702 is mainly used for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL) caused by infection of all HPV virus subtypes.
The product has been approved for international multi-center phase III clinical trials and is expected to Providing a new non-surgical treatment option can reduce the pain and side effects of surgical treatment for patients, especially to avoid the impact of surgery on the reproductive function of patients of reproductive age
.
In 2020, the number of HSIL patients in China is about 2 million, and the number is still growing
.
According to Asieris Pharma's forecast, the peak market penetration rates of APL-1202 and APL-1702 are 10%-50% and 10%-25% respectively, corresponding to a market space of RMB 1.
639 billion to RMB 4.
685 billion and RMB 1.
959 billion to RMB 4.
897 billion, respectively.
billion
.
It is worth mentioning that the two products, APL-1202 and APL-1702, were purchased by Asieris, not independently developed, and some of the core technologies of the two core products will cost more than 1 billion yuan.
It's a lot of pressure for a company with revenue
.
At the same time, the industry also pointed out that Asieris' core products also have competitors.
For example, in the domestic NMIBC field, in addition to Asieris' APL-1202, there are 6 innovative drugs of other companies in clinical stage; In the field of HSIL treatment, there are also 3 domestic therapeutic drugs targeting HSIL or CIN2/3 that have entered clinical trials
.
In addition, because the company has no sales team experience
.
In this regard, Asieris pointed out in the prospectus that in the future, the company's sales team may not be able to grasp the market demand for new drugs in a timely manner, respond to and serve the market in a timely manner, and the recruitment progress of the sales team is not as good as expected, and the loss of the sales team in the short term after entry.
These risks will have certain adverse effects on the commercialization of drugs
.
